A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
− Recently published retrospective studies in Urologic Oncology and Tomography assessed the impact of Androgen Deprivation Therapy (ADT) on Axumin PET imaging – BURLINGTON, Mass. & OXFORD, ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
VICTORVILLE — A new prostate cancer scan that is extending the lives of patients is now available in the High Desert. Axumin is a recently FDA-approved imaging agent that detects recurrent cancer ...
ARLINGTON, Va., October 26, 2020 -- Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free ...
Please provide your email address to receive an email when new articles are posted on . The addition of PET molecular imaging to conventional imaging helped guide treatment decisions that led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results